Business
-
Nephron Pharmaceuticals announced that the company is now offering 0.5% albuterol sulfate inhalation solution in 5 ml vials for direct shipping to US medical facilities in response to a nationwide shortage. Ritedose Pharmaceuticals recently announced… Read more . . .
-
The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded an $8.9 million grant to Pulmotect for continued development of the company’s PUL-042 immune stimulating inhalation solution, the company announced. Pulmotect said that the… Read more . . .
-
Aerami Therapeutics said that pre-clinical and Phase 1 data presented recently at ATS support advancing the company’s AER-901 nebulized imatinib into a Phase 2 trial that will include both patients with pulmonary arterial hypertension (PAH)… Read more . . .
-
Halo Therapeutics raises £1.5 million for Phase 1 trial of its pan-coronavirus antiviral nasal spray
Bristol University spinout Halo Therapeutics announced that it has raised £1.5 million in a funding round led by the Development Bank of Wales to support a Phase 1 trial of the company’s HTLX-1 linoleic acid… Read more . . .
-
SoftOx Solutions has announced a restructuring plan that includes shutting down its own GMP facility, laying off employees, and outsourcing further development of its SoftOx inhalation solution (SIS) to the University of Copenhagen. The company… Read more . . .
-
Lumen Bioscience said that it has received a contract worth $8.8 million from the Defense Innovation Unit (DIU) of the US Department of Defense for development of “a prototype broad-spectrum, fast-acting intranasal powder for treatment and prevention… Read more . . .
-
Hangzhou Chance Pharmaceuticals will pay Acorda Therapeutics $2.5 million up front for distribution rights to Inbrija levodopa DPI in China plus another $6 million in “a near term milestone payment” as well as $3 million… Read more . . .
-
Generics manufacturer Strides Pharma Science and CRO Orbicular Pharmaceutical Technologies, both based in India, have announced a new strategic partnership where Orbicular will formulate 4 nasal sprays to be manufactured and commercialized by Strides. According… Read more . . .
-
Bausch Health has announced the launch of Ryaltris olopatadine / mometasone furoate nasal spray for in Canada. Bausch Health acquired the Canadian rights to Ryaltris from Glenmark in March 2021, and Health Canada approved the… Read more . . .
-
Destiny Pharma and SporeGen have announced that Vietnamese biotechnology company Huro Biotech has acquired non-exclusive manufacturing rights for SPOR-COV bacillus nasal spray as well as exclusive marketing rights to the nasal spray in Vietnam. Huro… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden